Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility.
about
In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.Epidemiology of invasive candidiasis: a persistent public health problemIn Candida parapsilosis the ATC1 gene encodes for an acid trehalase involved in trehalose hydrolysis, stress resistance and virulence.Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.New and emerging yeast pathogensStatistical approaches to use a model organism for regulatory sequences annotation of newly sequenced speciesCandida pseudorugosa sp. nov., a novel yeast species from sputum.Genetic manipulation of the pathogenic yeast Candida parapsilosis.Candida albicans versus non-albicans bloodstream infection in patients in a tertiary hospital: an analysis of microbiological data.Cloning and characterization of a complex DNA fingerprinting probe for Candida parapsilosis.Successful treatment of Candida parapsilosis mural endocarditis with combined caspofungin and voriconazoleCandidemia at selected Canadian sites: results from the Fungal Disease Registry, 1992-1994. Fungal Disease Registry of the Canadian Infectious Disease Society.Evaluation of matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry for identification of Candida parapsilosis, C. orthopsilosis and C. metapsilosis.Biotyping and virulence properties of skin isolates of Candida parapsilosisElectrophoretic karyotype analysis of sequential Candida parapsilosis isolates from patients with persistent or pecurrent fungemia.Towards a targeted, risk-based, antifungal strategy in neutropenic patients.Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemiaA strategy for managing fungal infections in haematopoietic stem cell transplantation.Molecular genotyping of Candida parapsilosis group I clinical isolates by analysis of polymorphic microsatellite markers.Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in SpainOral candidal infections and antimycotics.Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003.Candida guilliermondii fungemia in patients with hematologic malignanciesCandida parapsilosis, an emerging fungal pathogenEpidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centersEpidemiology of nosocomial fungal infections.Antifungal prophylaxis during neutropenia and immunodeficiencyBiofilm formation by Candida species on the surface of catheter materials in vitro.Candida parapsilosis characterization in an outbreak setting.Targeted gene deletion in Candida parapsilosis demonstrates the role of secreted lipase in virulence.Epidemiology and echinocandin susceptibility of Candida parapsilosis sensu lato species isolated from bloodstream infections at a Spanish university hospital.Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.Three distinct genotypes within Candida parapsilosis from clinical sourcesPost intrastromal corneal ring segments insertion complicated by Candida parapsilosis keratitis.Nationwide study of candidemia, antifungal use, and antifungal drug resistance in Iceland, 2000 to 2011Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome.Candida parapsilosis fungemia in neonates: genotyping results suggest healthcare workers hands as source, and review of published studies.Antifungal agents in neonates: issues and recommendations.A case of Candida orthopsilosis associated septic arthritis in a patient with Systemic Lupus Erythematosus (SLE)Multisite reproducibility of colorimetric broth microdilution method for antifungal susceptibility testing of yeast isolates
P2860
Q28379512-CF0C8BA3-477C-4968-81C2-D29DB695BC95Q29616758-F6046603-6981-441C-B8BC-780263ABDC0DQ30412430-6FC668BC-96F4-41E3-AEA6-78483E2EC173Q30433993-A92999C0-08A8-442C-907B-732AACAFA351Q30452880-951F98A2-6433-44C5-8A7E-EAFFA7E4E5A1Q30566297-67CAC38F-F652-4A16-BEA5-16DF9CF5D050Q31064491-A2F9A8EF-027C-42E3-8B49-D0871F01447BQ31117831-50532F69-415F-4880-A211-8E95C09865CBQ31152900-47F49AF1-4D75-4722-9A7D-27AA1EA76189Q31850229-2DD6F39D-C3A2-4A40-BB2B-7D9A5DDEEAF4Q33239635-D05D98A2-381E-44FE-BA65-A908377AAD98Q33542339-B06B6048-BB50-4048-B10A-8BC628FA3EB6Q33891045-D5810BEC-19E9-4807-88E4-BC3F5AD4137EQ33963466-60F0EFDB-E788-4664-B4E3-C1603118EF9AQ33971783-F14DA11D-F93B-4997-BADE-3D67E2A15571Q34022479-17E45FC3-83C1-4FC0-86DC-3B2501DF843FQ34022724-F00B85F1-2839-4F03-AF10-BE316485BE3AQ34294925-1CF26B21-AD7C-421A-A087-D8DD641CEBE9Q34431664-4E9465C4-95A4-4483-8996-D94E455230C6Q34489579-A9FDA075-9454-4EEB-B523-ABCAEE2E2A54Q34632651-F5ABCCFC-EF57-44AE-9D94-25EC5D77C5A4Q34680777-5BCB4D68-5A6C-4154-A34A-CF6BB0212564Q34719843-1353BCCB-01C8-46E0-9684-30BCBE72F880Q34852747-3E38D7C1-65E8-4E46-97AA-80904AEE451AQ35073043-C4D2B6C9-7282-4A1E-8EC7-6C2FD1F7E0EAQ35372424-4E3D00A8-A35A-4306-8423-55CF4B7E1730Q35374928-38DFEB40-AF2A-4739-961B-0F0410B8861AQ35775012-CE90F276-8AD9-4BF2-B700-E23B24B5A483Q35880418-5EE3D09C-CC3D-41EE-AE4C-C89DEE38B5B3Q35987590-43C667F4-2A08-4921-9A09-E6E658F4BC3BQ36308069-3677ADD0-6796-4478-96D3-ECA8FF5EEB31Q36497888-72441578-E30B-4023-A0CD-BE451A844014Q36523267-F68EF690-46F2-48AE-9194-91957F1D9490Q36659404-19D4F8C7-4021-4892-B579-12E5619F5C8BQ36667530-B24D1743-42E8-44C3-B057-F9955D546D4EQ36822025-D14FDE89-7170-4FF8-BAA6-28D1EDB827D6Q36943829-60B517A9-4617-47A8-86C6-E763E81C2B21Q36967212-AC4BAD58-D780-48A9-838A-3D453C2BD8DDQ37009812-29273C3E-A0AB-4A80-A93C-7658FC18FD8DQ37087471-9F71E67E-9A8D-4BA1-B291-2CE9F0ACC93C
P2860
Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility.
description
1992 nî lūn-bûn
@nan
1992 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի մարտին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Candida parapsilosis: epidemio ...... antimicrobial susceptibility.
@ast
Candida parapsilosis: epidemio ...... antimicrobial susceptibility.
@en
type
label
Candida parapsilosis: epidemio ...... antimicrobial susceptibility.
@ast
Candida parapsilosis: epidemio ...... antimicrobial susceptibility.
@en
prefLabel
Candida parapsilosis: epidemio ...... antimicrobial susceptibility.
@ast
Candida parapsilosis: epidemio ...... antimicrobial susceptibility.
@en
P356
P1476
Candida parapsilosis: epidemio ...... antimicrobial susceptibility.
@en
P2093
Weems JJ Jr
P304
P356
10.1093/CLINIDS/14.3.756
P407
P577
1992-03-01T00:00:00Z